B-Raf inhibitor 1 is a potent and selective B-Raf inhibitor with cell IC50s of 0.31 μM and 2 nM for A375 proliferation and A375 p-ERK respectively.

XRK3F2 is a p62-ZZ domain inhibitor which can blunt MM-induced Runx2 suppression and induce new bone formation and remodeling.

LUT-014 is a B-Raf inhibitor with an IC50 of 11.7 nM, and it is developed to reduce dose-limiting acneiform lesions associated EGFR inhibitors treatment.

Donafenib, also known as CM-4307, is a multikinase inhibitor of Raf kinase and receptor tyrosine kinases with IC50 of 6 nM, 20 nM and 22 nM for Raf-1, B-Raf and VEGFR-3, respectively.

SB-590885 is a potent B-Raf inhibitor with Ki of 0.16 nM, 11-fold greater selectivity for B-Raf over c-Raf, no inhibition to other human kinases.

Doramapimod is a highly selective p38α MAPK inhibitor with Kd of 0.1 nM, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2, ZAP-70, EGFR, HER2, PKA, PKC, PKCα/β/γ.

Encorafenib is a potent and selective B-Raf^V600E inhibitor, with no significant activity observed against a panel of 100 kinases (IC50>900nM).

GDC-0879 is a potent, and selective B-Raf inhibitor with IC50 of 0.13 nM with activity against c-Raf as well, displaying no inhibition known to other protein kinases.

L-779450 is a potent, ATP-competitive Raf kinase inhibitor (IC50 =10 nM) that displays > 7, > 30 and > 70-fold selectivity over p38α, GSK3β and Lck respectively.

LY3009120 is a small molecule that has been shown to be a pan-RAF inhibitor of all isoforms, inhibiting BRAFV600E, BRAFWT and CRAFWT with IC50 values of 5.8, 9.1 and 15 nM and blocking proliferation in both BRAF and RAS mutant cells.

MLN 2480 is a selective inhibitor of pan-Raf kinase with antitumor activity.

PLX8394 is an inhibitor of B-Raf (V600E) with IC50 of 5 nM.